<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41806">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562131</url>
  </required_header>
  <id_info>
    <org_study_id>2015/163-4</org_study_id>
    <nct_id>NCT02562131</nct_id>
  </id_info>
  <brief_title>PET-MR-PSA Prostate Cancer Recidive Study</brief_title>
  <acronym>PET-MR-PSA</acronym>
  <official_title>18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent
      prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high
      molecular sensitivity of PET in a single imaging session. The aim of this study is to
      evaluate the sensitivity and specificity of simultaneous 18F-Fluciclovine PET/MRI for
      detection of recurrent prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients follow standard treatment and follow-up after the PET/MRI exam, which will be
      determined by the patient's treating urologist and/or oncologist. Data from histopathology,
      clinical follow-up and follow-up imaging will be collected to establish a reference standard
      that defines the presence or absence of disease for each patient. The imaging findings will
      be compared with the reference standard to assess the sensitivity and specificity. The
      diagnostic accuracy of combined PET/MRI and MRI-only (the current clinical standard) will be
      compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of recurrent prostate cancer by simultaneous 18F-Fluciclovine PET/MRI.</measure>
    <time_frame>10 years</time_frame>
    <description>Relevant patient information will be collected until 2027, 10 years after the last PET/MRI scan.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The aim in 2 years is 80 prostate cancer patients with biochemical relapse following
        radical treatment, or patients with persistently elevated PSA levels after radical
        prostatectomy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the criteria for biochemical relapse in accordance with the European Association of
             Urology (EAU) guidelines on prostate cancer must be fulfilled (two consecutive
             measurements with PSA &gt; 0.2 ng/ml following radical prostatectomy or PSA &gt; 2.0 ng/ml
             above the nadir following definitive radiotherapy)

          -  potential candidates for salvage treatment based on age and co-morbidity.

        Exclusion Criteria:

          -  general contra-indications for a PET/MRI exam (pacemaker, aneurysm clips, any form of
             metal in the body, or severe claustrophobia)

          -  impaired renal function defined as estimated glomerular filtration rate (eGFR) &lt; 30
             ml/min/1.73 m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tone F Bathen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Norwegian University of Science and Technology (NTNU)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torill E Sjøbakk, PhD</last_name>
    <phone>+47073598956</phone>
    <email>torill.sjobakk@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tone F Bathen, PhD</last_name>
    <phone>+47 73551355</phone>
    <email>tone.f.bathen@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Olavs Hospital, PET center</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne L Stokkan, PhD</last_name>
      <phone>+47 72825232</phone>
      <email>Marianne.Leirdal.Stokkan@stolav.no</email>
    </contact>
    <contact_backup>
      <last_name>Knut Haakon Stensæth, MD, PhD</last_name>
      <phone>+47 72829586</phone>
      <email>Knut.Haakon.Stenseth@stolav.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 11, 2016</lastchanged_date>
  <firstreceived_date>September 25, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET-MR</keyword>
  <keyword>recidive</keyword>
  <keyword>PET/MR imaging</keyword>
  <keyword>18F-Fluciclovine</keyword>
  <keyword>radical treatment</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
